Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Genomic Testing Challenges Persist

May 5th 2022

Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice.

Recent Advances in Treatment of MET Exon 14 Skipping Mutations in NSCLC

May 5th 2022

Dr Martin Dietrich provides an overview of how to treat MET exon 14 skipping mutations in non–small cell lung cancer.

Updates in Treatment of HER2 Mutant NSCLC

May 5th 2022

Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.

Nivolumab Plus Chemotherapy Moves Into Neoadjuvant Setting in NSCLC

May 4th 2022

Mark Awad, MD, PhD, discusses how the approval of nivolumab opens the door for the new regimen to become a backbone for future treatment strategies.

Recent Advances in Treatment of EGFR Exon 20 Insertion Mutations in NSCLC

May 2nd 2022

Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.

Updates in Treatment of NSCLC with Classical EGFR Mutations

May 2nd 2022

A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.

Dr. Weinberg on Treating Patients with NTRK Fusions in NSCLC

April 29th 2022

Frank Weinberg, MD, PhD, discusses the treatment options in non–small cell lung cancer harboring NTRK fusions.

IO Therapy in NSCLC With Concomitant KRAS/TP53 Mutations

April 29th 2022

Closing out her discussion on the management of actionable mutations in NSCLC, Meghan Mooradian, MD, highlights the detection and implications of KRAS/TP53 mutations.

Durvalumab Plus Oleclumab or Monalizumab Induces Increased Response Rates in NSCLC

April 28th 2022

Consolidation therapy with durvalumab and either oleclumab or monalizumab showed increased clinical benefits in patients with unresectable stage III non–small cell lung cancer.

Beyond the Clinic: Leveraging Research to Tackle Lung Cancer Disparities

April 27th 2022

Lung cancer remains the most common cause of cancer death in the United States.

Dr. Huang on Research in ALK+ NSCLC

April 26th 2022

Chao H. Huang, MD, FACP, discusses ongoing research around the use of ALK inhibitors for non–small cell lung cancer.

Adjuvant Atezolizumab Approaches EU Approval for High-Risk NSCLC With PD-L1 of ≥50%

April 22nd 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion supporting the approval of adjuvant atezolizumab, after complete resection and platinum-based chemotherapy, in adult patients with non–small cell lung cancer with a high risk of recurrence and whose tumors express PD-L1 of 50% or higher and do not harbor EGFR mutations or ALK alterations.

Poor Outcomes With IO Therapy in NSCLC With Concomitant KRAS/STK11 or KRAS/KEAP1 Mutations

April 22nd 2022

Expert perspective on the poor outcomes observed with immunotherapy in NSCLC with STK11 or KEAP1 mutations, alone or in combination with KRAS alterations.

Is There a Role for IO Therapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements?

April 22nd 2022

Insight on the outcomes seen with immunotherapy in non–small cell lung cancer with classical EGFR mutations or ALK rearrangements in the context of clinical study data.

FDA Grants Orphan Drug Designation to Toripalimab for Small Cell Lung Cancer

April 21st 2022

The FDA has granted an orphan drug designation to the PD-1 inhibitor toripalimab as a potential therapeutic option for patients with small cell lung cancer.

A Wealth of Clinical Trials Pushes the Treatment Landscape Forward Across Lung Cancer

April 20th 2022

David P. Carbone, MD, PhD, discusses the evolution of immunotherapy and targeted therapy in non–small cell lung cancer and the importance of biomarker testing for personalized therapy.

Challenges Associated with Molecular Testing in NSCLC

April 19th 2022

A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.

Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?

April 19th 2022

A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.

FDA Grants Priority Review to Trastuzumab Deruxtecan for Previously Treated HER2-Mutant NSCLC

April 19th 2022

The FDA has accepted for priority review a supplemental biologics license application for trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic non–small cell lung cancer whose tumors have a HER2 mutation and who have received a prior systemic therapy.

Frontline Therapy Advances Are Current Focus in SCLC and NSCLC

April 18th 2022

Lung cancer management methods are rapidly evolving to encompass immunotherapy in the frontline setting and approved second-line options with tyrosine kinase inhibitors and monoclonal antibodies in non–small cell lung cancer, as well as treatment advances in first- and second-line small cell lung cancer.